Followers | 602 |
Posts | 29851 |
Boards Moderated | 1 |
Alias Born | 01/30/2012 |
Tuesday, April 25, 2023 4:50:21 PM
“Phase III trials
The experimental study drug or treatment is given to large groups of people. Researchers confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the experimental drug or treatment to be used safely.4 Jan 2018”
“Phase 3 trials are conducted in 300-3,000 volunteers who have the disease or medical condition to further assess safety, performance, and side effects. About 25% of medications will perform well enough in Phase 3 trials to move forward in the FDA approval process.7 Jan 2021”
“Phase III clinical trials compare the safety and effectiveness of the new treatment against the current standard treatment. Because doctors do not yet know which treatment is better, study participants are often picked at random (called randomized) to get either the standard treatment or the new treatment.18 Aug 2020”
There it’s all there for whoever wants to read it!
My post are my opinion only. You should do your own due diligence before investing in any stock or take professional advice. I am not an investment advisor. Kind Regards.
Recent VIRI News
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2024 12:15:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2024 01:25:13 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/17/2024 08:30:26 PM
- Form SC 13D - General Statement of Acquisition of Beneficial Ownership • Edgar (US Regulatory) • 10/15/2024 08:19:38 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/07/2024 12:06:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/07/2024 12:02:34 PM
- Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”) • GlobeNewswire Inc. • 10/07/2024 11:05:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 02:15:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 01:30:13 PM
- Virios Therapeutics Announces Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/08/2024 01:15:00 PM
- Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024 • GlobeNewswire Inc. • 08/01/2024 01:41:56 PM
- Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center • GlobeNewswire Inc. • 07/23/2024 01:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 01:15:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/12/2024 01:15:20 PM
- Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study • GlobeNewswire Inc. • 05/22/2024 05:30:00 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 05/20/2024 08:05:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 01:28:00 PM
- Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study • GlobeNewswire Inc. • 05/20/2024 12:53:09 AM
- Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study • GlobeNewswire Inc. • 05/17/2024 08:10:00 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 05/17/2024 08:01:45 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 02:30:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:01:31 PM
- Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/09/2024 11:45:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 09:25:53 PM
FEATURED SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • Nov 7, 2024 8:48 AM
FEATURED SBC Medical Group Holdings and MEDIROM Healthcare Technologies Announce Business Alliance • Nov 7, 2024 7:00 AM
Rainmaker Worldwide Inc. (OTC: RAKR) Announces Successful Implementation of 1.6 Million Liter Per Day Wastewater Treatment Project in Iraq • RAKR • Nov 7, 2024 8:30 AM
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM
Rainmaker Worldwide Inc. Announces Strategic Partnership Between Miranda Water Technologies and Fleming College • RAKR • Nov 4, 2024 12:03 PM
North Bay Resources Announces Assays up to 9.5% Copper at Murex Copper Project, British Columbia • NBRI • Nov 4, 2024 9:00 AM